Literature DB >> 2050598

The Garrod lecture. Progress in understanding urinary infections.

W Brumfitt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2050598     DOI： 10.1093/jac/27.1.9

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  4 in total

1.  The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients.

Authors:  Ebbing Lautenbach; Joshua P Metlay; Xiangqun Mao; Xiaoyan Han; Neil O Fishman; Warren B Bilker; Pam Tolomeo; Mary Wheeler; Irving Nachamkin
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

2.  Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance.

Authors:  Ebbing Lautenbach; Joshua P Metlay; Mark G Weiner; Warren B Bilker; Pam Tolomeo; Xiangqun Mao; Irving Nachamkin; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2009-01       Impact factor: 3.254

3.  Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.

Authors:  R Mattina; C E Cocuzza; M Cesana
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

4.  Assessment of the use of urine samples to detect colonization with fluoroquinolone-susceptible and fluoroquinolone-resistant Escherichia coli.

Authors:  Ebbing Lautenbach; Andrew Babson; Evelyn Santana; Pam Tolomeo; Nicole Black; Catherine A Smith; Joel Maslow
Journal:  Infect Control Hosp Epidemiol       Date:  2009-04       Impact factor: 3.254
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.